Adma Biologics (ADMA) closed at $10.6 in the latest trading session, marking a -2.75% move from the prior day.
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...
Recently, Canaccord Genuity initiated coverage on ADMA Biologics with a positive view, while the company addressed a short-seller report by rejecting its claims and highlighting strong demand for its ...
Zacks Investment Research on MSN
ADMA vs Takeda: Which plasma therapy stock is the better buy today?
ADMA Biologics ADMA and Takeda TAK are prominent players in the plasma-derived immunoglobulin space. ADMA focuses on ...
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADMA BIOLOGICS, INC. (ADMA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Year-End 2025 Cash Grew to Approximately $88 Million with an Unaudited Operating Cash Flow Estimate of $40 Million in 4Q 2025 2026 Expected to be ADMA's First Full Year of Yield-Enhanced Production, ...
The MarketWatch News Department was not involved in the creation of this content. Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business ...
The Summers Value Fund LP returned -2.7% net in Q1 2026, underperforming the Russell 2000 Index ETF, which returned 0.9%, and the Russell 2000 Value Index ETF, which returned 4.9%. According to its ...
ADMA Biologics’ ADMA shares have plunged 42.5% year to date against the industry’s growth of 1.6%. The stock has also underperformed the sector and the S&P 500 in this time frame. Much of this ...
ADMA announced the FDA's approval of its yield enhancement process. The company's yield enhancement process has demonstrated the ability to increase production yields by approximately 20%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results